Although CV outcomes trials with GLP-1RAs (LEADER and SUSTAIN-6) and SGLT2 inhibitors (EMPA-REG OUTCOME and CANVAS) showed significantly reduced occurrences of the pre-specified primary composite endpoint comprised of CV death, non-fatal myocardial infarction, and non-fatal stroke in T2D patients at high risk of CV events, the treatment effects on the individual components of the primary composite endpoint differed between drug classes, and even between different members of the same class [22, 23]
Where Is My Order Why hasnt my order shipped yet
J., Adam, K
Our bodies change throughout our lives, so its never too early to understand whats happening and what we can do about it
Rainero, I., Govone, F., Gai, A., Vacca, A
Improper storage conditions, such as extended exposure to direct sunlight, high heat & humidity, can cause product degradation over time.